# Nature

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/nature
Canonical HTML page: https://getbiobrief.com/entity/nature

## Timeline

- **2026-07-26**: University investigation launched — Shanghai Jiao Tong University School of Medicine announces a special working group to investigate and promises 'serious action'.
- **2026-07-23**: Investigative report published — Science and Retraction Watch publish a joint exposé revealing the death and lack of disclosure, triggering international scrutiny.
- **2025**: Mei receives gene-editing therapy — Six-year-old girl with rare cognitive delay condition receives spinal infusion of trillions of engineered viruses in an experimental trial.
- **2025**: Mei dies after therapy — Mei dies approximately one week after the infusion; the death is not reported publicly at the time.

## Recent coverage (2 stories)

### Casdatifan’s Phase 1 Data in 127 Kidney Cancer Patients Fuel HIF-2α Competition
2026-07-28 03:57:26 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Oral HIF-2α inhibitor casdatifan posted durable responses in the ARC-20 phase 1 trial of 127 heavily pretreated ccRCC patients, published in Nature. The data intensifies competition in the HIF-2α space, where Merck’s belzutifan is already approved, and sets the stage for pivotal trials.
Full story: https://getbiobrief.com/story/casdatifan-phase1-hif2a-competition

### Gene-Editing Death Rocks Biotech: Trillion-Virus Trial Under Investigation
2026-07-26 14:14:01 · Sentiment: Very Bearish · Impact: 9/10 · Sources: 2

The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments.
Full story: https://getbiobrief.com/story/gene-editing-death-biotech-investigation-ethics

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.